{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T20:26:31Z","timestamp":1788207991195,"version":"build-2803163510"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jcf.2026.08.008","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T20:05:33Z","timestamp":1788206733000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Peripheral muscle dysfunction persists in the era of highly effective CFTR modulators in cystic fibrosis"],"prefix":"10.1016","author":[{"given":"Antoine","family":"Bronstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Zitta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oussama","family":"Saidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nad\u00e8ge","family":"Goriot-Raynaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Mely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2658-277X","authenticated-orcid":false,"given":"Mathieu","family":"Gruet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2026.08.008_bib0001","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1002\/ppul.26970","article-title":"SHIFTing goals in cystic fibrosis\u2014managing extrapulmonary disease in the era of CFTR modulator therapy; proceedings of the international shaping initiatives and future trends (SHIFT) symposium","volume":"59","author":"O\u2019Donnell","year":"2024","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2026.08.008_bib0002","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jcf.2017.02.007","article-title":"Peripheral muscle abnormalities in cystic fibrosis: etiology, clinical implications and response to therapeutic interventions","volume":"16","author":"Gruet","year":"2017","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.08.008_bib0003","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1007\/s00421-026-06130-y","article-title":"Peripheral muscle oxygenation during upper extremity functional exercise and balance in pediatric patients with cystic fibrosis: a cross-sectional study","volume":"126","author":"Yoleri","year":"2026","journal-title":"Eur J Appl Physiol"},{"key":"10.1016\/j.jcf.2026.08.008_bib0004","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.71044","article-title":"Peripheral muscle function and body composition in people with cystic fibrosis on elexacaftor\/tezacaftor\/ivacaftor: a cross-sectional single-centre study","volume":"60","author":"Clayton","year":"2025","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2026.08.008_bib0005","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.ajcnut.2025.09.019","article-title":"Relationship between skeletal muscle indicators and clinical outcomes in cystic fibrosis is modified by adiposity and CFTR modulator use: a cross-sectional analysis","volume":"122","author":"Gonzalez Ramirez","year":"2025","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jcf.2026.08.008_bib0006","article-title":"One year effect of tezacaftor and ivacaftor on functional exercise capacity and muscle strength in people with cystic fibrosis","volume":"10","author":"Aubriot","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.jcf.2026.08.008_bib0007","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jcf.2024.11.003","article-title":"What does it mean to be \u201chealthy\u201d when taking elexacaftor\/tezacaftor\/ivacaftor (ETI)? A qualitative study","volume":"24","author":"Everhart","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.08.008_bib0008","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/j.jcf.2021.08.004","article-title":"Rethinking physical exercise training in the modern era of cystic fibrosis: a step towards optimising short-term efficacy and long-term engagement","volume":"21","author":"Gruet","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.08.008_bib0009","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jcf.2026.03.026","article-title":"Changes in nutritional priorities and management in people with CF","volume":"25","author":"Alvarez","year":"2026","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.08.008_bib0010","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0029-2023","article-title":"Guidance and standard operating procedures for functional exercise testing in cystic fibrosis","volume":"32","author":"Saynor","year":"2023","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.jcf.2026.08.008_bib0011","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jelekin.2009.05.001","article-title":"Long term reliability of EMG measurements in adults with cystic fibrosis","volume":"20","author":"Gruet","year":"2010","journal-title":"J Electromyogr Kinesiol"},{"key":"10.1016\/j.jcf.2026.08.008_bib0012","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1080\/02640414.2014.996184","article-title":"The validity and reliability of an iPhone app for measuring vertical jump performance","volume":"33","author":"Balsalobre-Fernandez","year":"2015","journal-title":"J Sports Sci"},{"key":"10.1016\/j.jcf.2026.08.008_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2026.05.013","article-title":"Impact of ETI therapy on bone health, body composition and cardiopulmonary fitness in children with CF","author":"Holden","year":"2026","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.08.008_bib0014","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jcf.2025.10.005","article-title":"Limited impact of elexacaftor\/tezacaftor\/Ivacaftor on CPET outcomes in an Italian cohort of people with Cystic Fibrosis: reinforcing the essential role of exercise training","volume":"25","author":"Retucci","year":"2026","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.08.008_bib22","doi-asserted-by":"crossref","unstructured":"Aubriot A.-S., Song C., Gon\u00e7alv\u00e8s C., Santel\u00e9 L., Berardis S., Goubau C., et al. Improvement in functional exercise performance and quadriceps muscle strength after two years treatment with elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: A prospective observational study. J Cyst Fibros. 2026:S1569-1993(26)01657-7. doi:10.1016\/j.jcf.2026.07.003.","DOI":"10.1016\/j.jcf.2026.07.003"},{"key":"10.1016\/j.jcf.2026.08.008_bib0015","doi-asserted-by":"crossref","DOI":"10.1111\/sms.14564","article-title":"Effects of a remotely supervised resistance training program on muscle strength and body composition in adults with cystic fibrosis: randomized controlled trial","volume":"34","author":"Sosa-Pedreschi","year":"2024","journal-title":"Scand J Med Sci Sports"},{"key":"10.1016\/j.jcf.2026.08.008_bib0016","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1017\/S0007114525103760","article-title":"Dietary protein intake and overall diet quality in adults with cystic fibrosis following elexacaftor\/tezacaftor\/ivacaftor therapy","volume":"133","author":"Morgan","year":"2025","journal-title":"Br J Nutr"},{"key":"10.1016\/j.jcf.2026.08.008_bib0017","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.jcf.2025.02.001","article-title":"Cardiovascular function in people with cystic fibrosis on Elexacaftor\/Tezacaftor\/Ivacaftor: a cross-sectional, observational, single-centre study","volume":"24","author":"Clayton","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.08.008_bib0018","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.21982","article-title":"Cystic fibrosis transmembrane conductance regulator in human muscle: dysfunction causes abnormal metabolic recovery in exercise","volume":"67","author":"Lamhonwah","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jcf.2026.08.008_bib0019","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1113\/JP272486","article-title":"CrossTalk proposal: skeletal muscle oxidative capacity is altered in patients with cystic fibrosis","volume":"595","author":"Rodriguez-Miguelez","year":"2017","journal-title":"J Physiol"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156919932603729X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156919932603729X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T20:05:36Z","timestamp":1788206736000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156919932603729X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":20,"alternative-id":["S156919932603729X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2026.08.008","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peripheral muscle dysfunction persists in the era of highly effective CFTR modulators in cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2026.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}